Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study
Authors' conclusion
Despite the lack of a favorable effect on cardiac remodeling, SGLT-2i treatment significantly improved LV systolic and diastolic function, left atrial (LA) reservoir and total emptying function, RV systolic function and pulmonary artery pressure.
Study context
- Population
- Individuals with T2D and heart failure with reduced ejection fraction (HFrEF) treated with SGLT2i
- Participants
- 31 individuals
- Exposure
- SGLT2i treatment: baseline vs 6 months
- SGLT2in = 31
- Outcome
- Echocardiographic signs of favorable reverse remodeling
- Follow-up
- 6 months
Methodological detailspilot, single-group, longitudinal
- Pilot
- Single-group
- Longitudinal
Main finding
As reported in the abstract
Echocardiographic parameters
- Left ventricular ejection fraction (LVEF), global work index, global work efficiency, global longitudinal strain (GLS), left atrial (LA) expansion index, total LA emptying fraction, tricuspid annular plane systolic excursion (TAPSE), septal thickness, pulmonary artery systolic pressures (PASP) and TAPSE/PASP ratio significantly improved
Observational data: associations, not effects.
Original publication
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study. Diabetes Res Clin Pract. Published 25 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →